ADAP

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Price Reaction to Earnings Reports

View detailed tables showing price action before and after earnings announcements, ranging from intraday to one week out. Track how the market has reacted to past earnings to identify patterns and predict future behavior. Click here to open.

Dollar change -0.0514
Percentage change -8.14	%

Peers: IOVA FATE ALLO ADPT BLRX CGEN AFMD IMTX TPST

| Held by: SPDW FESM GWX QQQS

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-0.21	Insider Own	11.49%	Shs Outstand	255.70M	Perf Week	-11.85%
Market Cap	148.44M	Forward P/E	-	EPS next Y	-0.08	Insider Trans	-0.08%	Shs Float	226.49M	Perf Month	-24.72%
Income	-45.01M	PEG	-	EPS next Q	-0.03	Inst Own	42.01%	Short Float	2.97%	Perf Quarter	-44.75%
Sales	175.60M	P/S	0.85	EPS this Y	70.37%	Inst Trans	-22.02%	Short Ratio	4.01	Perf Half Y	-42.56%
Book/sh	0.31	P/B	1.85	EPS next Y	-212.49%	ROA	-14.66%	Short Interest	6.72M	Perf Year	14.01%
Cash/sh	0.73	P/C	0.80	EPS next 5Y	-	ROE	-53.54%	52W Range	0.43 - 2.05	Perf YTD	-26.85%
Dividend Est.	-	P/FCF	-	EPS past 5Y	10.30%	ROI	-29.94%	52W High	-71.70%	Beta	2.18
Dividend TTM	-	Quick Ratio	3.82	Sales past 5Y	134.88%	Gross Margin	93.57%	52W Low	34.91%	ATR (14)	0.06
Dividend Ex-Date	-	Current Ratio	3.85	EPS Y/Y TTM	57.01%	Oper. Margin	-32.90%	RSI (14)	32.52	Volatility	8.04% 9.78%
Employees	449	Debt/Eq	0.93	Sales Y/Y TTM	145.37%	Profit Margin	-25.63%	Recom	1.89	Target Price	2.71
Option/Short	Yes / Yes	LT Debt/Eq	0.88	EPS Q/Q	65.25%	Payout	-	Rel Volume	1.81	Prev Close	0.63
Sales Surprise	115.68%	EPS Surprise	-5.26%	Sales Q/Q	467.86%	Earnings	Nov 14 BMO	Avg Volume	1.68M	Price	0.58
SMA20	-12.05%	SMA50	-22.70%	SMA200	-45.37%	Trades		Volume	3,033,080	Change	-8.14%

Date	Action	Analyst	Rating Change	Price Target Change
Jul-30-24	Initiated	H.C. Wainwright	Buy	$4
May-30-24	Initiated	Scotiabank	Sector Outperform	$3.15
Mar-24-23	Initiated	Bryan Garnier	Buy	$3.60
Jan-03-23	Upgrade	Guggenheim	Neutral → Buy	$5
Nov-09-22	Upgrade	Mizuho	Neutral → Buy	$9
May-28-21	Initiated	Barclays	Underweight	$4
Apr-22-20	Initiated	Mizuho	Neutral	$3
Aug-02-19	Downgrade	Guggenheim	Buy → Neutral
May-31-19	Initiated	ROTH Capital	Buy
May-30-19	Resumed	Citigroup	Buy
May-07-19	Downgrade	SVB Leerink	Outperform → Mkt Perform	$12 → $5
Mar-17-17	Initiated	Wells Fargo	Market Perform
Oct-24-16	Downgrade	BofA/Merrill	Neutral → Underperform
Sep-30-16	Initiated	Raymond James	Outperform	$16
Feb-25-16	Initiated	Citigroup	Buy	$15
Jun-01-15	Initiated	Leerink Partners	Outperform	$24
Jun-01-15	Initiated	Guggenheim	Buy
Jun-01-15	Initiated	BofA/Merrill	Neutral

Show Previous Ratings

Dec-02-24 04:00PM	First Patient Treated with Adaptimmune's TECELRA(R) (afamitresgene autoleucel) (Newsfile)
Nov-15-24 05:00AM	Halozyme bids for Evotec; BeiGene gets a new name (BioPharma Dive)
Nov-14-24 11:55AM	Adaptimmune nears second sarcoma approval as Phase II trial hits endpoints (Pharmaceutical Technology) -23.28%
02:15AM	Adaptimmune Therapeutics PLC (ADAP) Q3 2024 Earnings Call Highlights: Strategic Restructuring ... (GuruFocus.com)
Nov-13-24 04:05PM	Adaptimmune Reports Q3 2024 Financial and Business Updates (Newsfile)
09:00AM	Loading…
09:00AM	Adaptimmune's Lete-cel Achieves Primary Endpoint in Pivotal Trial (Newsfile)
Nov-05-24 09:19AM	Adaptimmune to Participate in Scientific and Medical Conferences this November and December (Newsfile)
Oct-31-24 05:20PM	Adaptimmune to Report Q3 2024 Financial and Business Updates on Wednesday, November 13, 2024 (Newsfile) +10.23%
Sep-20-24 08:35AM	Life Sciences Virtual Investor Forum Presentations Now Available for Online Viewing (GlobeNewswire)
Sep-16-24 12:07PM	Life Sciences Virtual Investor Forum Agenda Announced for September 19th (GlobeNewswire) -5.41%
Aug-28-24 08:00AM	Adaptimmune to Participate in Two Bank Conferences this September (Newsfile)
Aug-12-24 07:00AM	Adaptimmune Reports Q2 2024 Financial and Business Updates (Newsfile) +9.82%
Aug-09-24 07:13AM	Adaptimmune leads in soft tissue sarcoma therapy with first TCR approval (Pharmaceutical Technology)
Aug-05-24 08:00AM	Adaptimmune to Report Q2 2024 Financial and Business Updates on Monday, August 12, 2024 (Newsfile) -16.24%
Aug-02-24 11:53AM	Adaptimmunes Tecelra gains accelerated approval for synovial sarcoma (Pharmaceutical Technology) -7.87%
08:46AM	Loading…
08:46AM	FDA Approves Adaptimmune Therapeutics' Engineered Cell Therapy As First For Solid Tumor And New Therapy For Rare Soft Tissue Cancer In Over A Decade (Benzinga)
06:54AM	First-of-its-kind cell therapy approved by FDA for rare soft tissue cancer (BioPharma Dive)
Aug-01-24 08:20PM	Adaptimmune Receives U.S. FDA Accelerated Approval of TECELRA (afamitresgene autoleucel), the First Approved Engineered Cell Therapy for a Solid Tumor (Business Wire)
Jul-24-24 11:13PM	Why Are Hedge Funds Bullish on Adaptimmune Therapeutics plc (ADAP) Now? (Insider Monkey) +5.69%
Jul-03-24 11:11AM	3 Biotech Moonshots With Imminent Catalyst Potential (InvestorPlace)
06:00AM	5 FDA decisions to watch in the third quarter (BioPharma Dive)
Jun-03-24 12:00PM	Adaptimmune to Present Data from Planned Interim Analysis of Pivotal IGNYTE-ESO Trial with Lete-cel at ASCO; Data Continue to Support further Development of Sarcoma Franchise (Newsfile) -5.31%
May-31-24 07:39AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday (InvestorPlace) +11.88%
May-30-24 04:01PM	Galapagos and Adaptimmune sign clinical collaboration agreement with an option to exclusively license Adaptimmune's TCR T-cell therapy candidate, uza-cel, in head & neck cancer and potential future solid tumor indications (GlobeNewswire)
04:01PM	Adaptimmune and Galapagos Sign Clinical Collaboration Agreement with an Option to Exclusively License Adaptimmune's TCR T-cell Therapy Candidate, uza-cel, in Head & Neck Cancer and Potential Future Solid Tumor Indications (Newsfile)
May-17-24 06:49AM	Mizuho Slashes Price Target on Adaptimmune Therapeutics to $3 From $9, Keeps Buy Rating (MT Newswires) -7.50%
May-16-24 08:18AM	Adaptimmune Therapeutics plc (NASDAQ:ADAP) Q1 2024 Earnings Call Transcript (Insider Monkey)
May-15-24 12:53PM	ADAP Stock Earnings: Adaptimmune Therapeutics Misses EPS, Misses Revenue for Q1 2024 (InvestorPlace) +7.83%
11:07AM	Adaptimmune Therapeutics Enters Into $125 Million Term Loan Facility With Hercules Capital (MT Newswires)
07:30AM	Adaptimmune Reports Q1 2024 Financial and Business Updates (Newsfile)
07:00AM	Loading…
07:00AM	Adaptimmune Secures up to $125 Million Debt Financing with Hercules Capital (Newsfile)
May-01-24 12:00PM	Adaptimmune to Report Q1 2024 Financial and Business Updates on Wednesday, May 15, 2024 (Newsfile)
Apr-23-24 07:45AM	Garry Menzel joins GHO Capital as Operating Partner (GlobeNewswire) +12.87%
Apr-15-24 02:12PM	Adaptimmune (ADAP) Down on End of Collaboration With Roche (Zacks) -9.48%
Apr-12-24 08:00AM	Strategic Collaboration between Adaptimmune and Genentech to Research, Develop, and Commercialize Cancer-targeted Allogeneic T-cell Therapies Terminated (Newsfile) -10.08%
05:37AM	Roche, Adaptimmune part ways on cell therapy research (BioPharma Dive)
Mar-27-24 07:30PM	Results of Adaptimmune's SPEARHEAD-1 Trial with Afami-cel in Advanced Sarcomas Published in the Lancet (Newsfile)
Mar-07-24 01:42PM	Adaptimmune Therapeutics PLC Reports Q4 and Full Year 2023 Financial Results (GuruFocus.com)
08:24AM	Adaptimmune Therapeutics plc (NASDAQ:ADAP) Q4 2023 Earnings Call Transcript (Insider Monkey)
Mar-06-24 12:52PM	ADAP Stock Earnings: Adaptimmune Therapeutics Misses EPS, Misses Revenue for Q4 2023 (InvestorPlace) +17.12%
07:00AM	Adaptimmune Reports Q4/Full Year 2023 Financial Results and Business Updates (Newsfile)
Feb-27-24 08:00AM	Adaptimmune Hires Chief Commercial Officer in Advance of Q3 2024 PDUFA Date for Afami-cel, a Late-stage Product in the Company's Sarcoma Franchise (Newsfile)
Feb-21-24 04:00PM	Adaptimmune to Report Q4 and Full Year 2023 Financial and Business Updates on Wednesday, March 6, 2024 (Newsfile) +19.05% -8.00%
Feb-16-24 03:57AM	15 Top Performing European Stocks So Far in 2024 (Insider Monkey)
Feb-13-24 06:15PM	Adaptimmune Therapeutics PLC (ADAP) Stock Moves -1.24%: What You Should Know (Zacks) +7.11%
Jan-31-24 04:44PM	Adaptimmune Announces U.S. FDA Acceptance of Biologics License Application for Afami-cel for the Treatment of Advanced Synovial Sarcoma with Priority Review (Newsfile) +9.74%
Jan-30-24 01:02PM	Baillie Gifford Increases Stake in Adaptimmune Therapeutics PLC (GuruFocus.com) +10.18%
Jan-16-24 11:17AM	Adaptimmune (ADAP) Surges More Than 80% in a Month: Here's Why (Zacks) -13.72%
Jan-04-24 07:37AM	Adaptimmune Projects Sarcoma Franchise to Deliver US Peak Year Sales up to $400 Million - Presentation at JP Morgan Healthcare Conference (Newsfile) +12.40%
Dec-06-23 07:00AM	Adaptimmune Completes Submission of Rolling Biologics License Application (BLA) to U.S. FDA for Afami-cel for the Treatment of Advanced Synovial Sarcoma (Newsfile)
Nov-30-23 10:52AM	Adaptimmune (ADAP) Rises as GSK Transfers T-Cell Therapy IND (Zacks)
Nov-29-23 08:00AM	Adaptimmune Receives Transfer of IND for Lete-cel Program (Newsfile) +11.66%
Nov-13-23 09:35AM	Adaptimmune Therapeutics PLC (ADAP) Loses -28.34% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner (Zacks)
08:35AM	Adaptimmune Therapeutics plc (NASDAQ:ADAP) Q3 2023 Earnings Call Transcript (Insider Monkey)
Nov-08-23 07:30AM	Adaptimmune Reports Third Quarter Financial Results and Business Update (Newsfile) -5.57%
07:05AM	Adaptimmune Selects ADP-600 as Clinical Candidate for Best-in Class PRAME Strategy (Newsfile)
Nov-07-23 06:15PM	Adaptimmune Therapeutics PLC (ADAP) Surpasses Market Returns: Some Facts Worth Knowing (Zacks)
Oct-31-23 08:00AM	Adaptimmune Reports Positive Data with Lete-cel[1] from an Interim Analysis of the Pivotal IGNYTE-ESO Trial for People with Synovial Sarcoma or MRCLS (Newsfile)
08:00AM	Adaptimmune Reports Better Outcomes for People with Synovial Sarcoma who Received Afami-cel Compared to Historical Control (Newsfile)
Oct-27-23 06:15PM	Adaptimmune Therapeutics PLC (ADAP) Suffers a Larger Drop Than the General Market: Key Insights (Zacks)
Oct-25-23 08:06AM	Adaptimmune to Report Q3 2023 Financial and Business Updates on Wednesday, November 8, 2023 (Newsfile)
Oct-23-23 04:15AM	Next-Generation TCR T-cell Therapy (ADP-A2M4CD8) Demonstrates Strong Efficacy in a Broad Range of Solid Tumors; Adaptimmune Presents Data Update from its SURPASS trial at ESMO (Newsfile) +6.25%
Sep-11-23 08:00AM	Dr. Karen Chagin Joins Adaptimmune as Senior Vice President of Early-Stage Development (Newsfile) +8.81%
Aug-09-23 07:29AM	Adaptimmune Reports Second Quarter Financial Results and Business Update (Newsfile)
Aug-03-23 01:24PM	Adaptimmune to Report Q2 2023 Financial and Business Updates on Wednesday, August 9, 2023 (Newsfile)
Jul-28-23 12:30PM	Adaptimmune (ADAP) to Report Q2 Earnings: What's in the Cards? (Zacks)
Jul-20-23 07:28AM	Investors in Adaptimmune Therapeutics (NASDAQ:ADAP) from five years ago are still down 90%, even after 12% gain this past week (Simply Wall St.) -10.10%
Jul-16-23 08:18PM	Arcturus Therapeutics (ARCT) Surges 15.0%: Is This an Indication of Further Gains? (Zacks)
Jun-29-23 09:18AM	Reata's (RETA) Skyclarys PAS Gets FDA Nod, Stock Rises 7% (Zacks)
Jun-26-23 11:23AM	AbbVie (ABBV) Gets CHMP Positive Opinion for Atogepant Approval (Zacks)
11:15AM	Novo Nordisk (NVO) Posts Upbeat Once-Weekly Insulin Icodec Data (Zacks)
Jun-23-23 09:15AM	Horizon's (HZNP) Tepezza Study in Japan for TED Meets Goal (Zacks)
Jun-22-23 09:40AM	Amgen's (AMGN) Blincyto sBLA Gets FDA Nod in Treating Leukemia (Zacks)
Jun-19-23 10:18AM	GSK Announces Extension of FDA Review for Rare Blood Therapy (Zacks)
Jun-16-23 08:39AM	Iovance (IOVA) Updates on Combo Drug in Advanced Melanoma Study (Zacks)
Jun-15-23 09:43AM	Lava (LVTX) Discontinues Hematological Tumor Study, Shares Fall (Zacks)
08:18AM	IO Biotech (IOBT) Down Despite Positive Update on Melanoma Study (Zacks)
Jun-13-23 10:14AM	AstraZeneca (AZN) Breast Cancer Combo Drug Gets Priority Review (Zacks)
Jun-12-23 10:00AM	Editas (EDIT) Posts Upbeat Initial Data From SCD & TDT Studies (Zacks) +5.33%
09:48AM	AstraZeneca (AZN) & Quell to Co-Develop Autoimmune Cell Therapies (Zacks)
Jun-09-23 10:52AM	Merck's (MRK) Keytruda for Liver Cancer to Undergo FDA Review (Zacks)
Jun-06-23 06:50AM	Dr. Reddy's (RDY) Meets Goals in Actemra Biosimilar Study (Zacks)
Jun-05-23 11:40AM	Novo Nordisk (NVO) Gears Up to Acquire BIOCORP for 154M Euros (Zacks)
10:22AM	Bristol Myers (BMY) Announces Upbeat Data From NSCLC Study (Zacks)
Jun-01-23 03:29PM	Adaptimmune Announces Completion of Strategic Combination with TCR2 Therapeutics Creating a Preeminent Solid Tumor Cell Therapy Company (Newsfile) +6.86%
May-30-23 09:35AM	Down -22.38% in 4 Weeks, Here's Why You Should You Buy the Dip in Adaptimmune Therapeutics PLC (ADAP) (Zacks)
May-25-23 05:00PM	Adaptimmune Announces 70% of People with Advanced Synovial Sarcoma Who Respond to Afami-cel are Alive Two Years Post-Treatment; Data from Cohort 1 of SPEARHEAD-1 to be Presented at ASCO (Newsfile) -5.13%
May-12-23 07:29AM	Adaptimmune Reports First Quarter Financial Results and Business Update (Newsfile)
May-09-23 06:43AM	Is Adaptimmune Therapeutics (NASDAQ:ADAP) In A Good Position To Invest In Growth? (Simply Wall St.)
May-05-23 05:00AM	Zacks.com featured highlights Sweetgreen, Adaptimmune Therapeutics, Owl Rock Capital, MACOM Technology Solutions and Equity Commonwealth (Zacks)
Apr-28-23 12:00PM	Adaptimmune to Report Q1 2023 Financial and Business Updates on Friday, May 12, 2023 (Newsfile)
Apr-18-23 11:49AM	Adaptimmune Therapeutics plc (NASDAQ:ADAP) Looks Inexpensive But Perhaps Not Attractive Enough (Simply Wall St.)
Apr-12-23 10:42AM	Adaptimmune (ADAP) Up 7%, Gets T-Cell Programs Rights From GSK (Zacks)
Apr-11-23 12:13PM	Why Shares of Adaptimmune Therapeutics Jumped Tuesday (Motley Fool) +7.08%
08:00AM	Adaptimmune and GSK Have Agreed Terms for Transfer of PRAME and NY-ESO Target Programs back to Adaptimmune (Newsfile)
Mar-08-23 07:14AM	Adaptimmune Therapeutics plc (NASDAQ:ADAP) Q4 2022 Earnings Call Transcript (Insider Monkey)
05:23AM	News Flash: Analysts Just Made A Huge Upgrade To Their Adaptimmune Therapeutics plc (NASDAQ:ADAP) Forecasts (Simply Wall St.)
Mar-06-23 01:08PM	Adaptimmune Agrees To Merge With Another Cell Therapy Focused Company (Benzinga) -25.00%
06:30AM	Adaptimmune Reports Fourth-Quarter and Full Year Financial Results and Business Update (Newsfile)
06:00AM	Adaptimmune and TCR2 Therapeutics Announce Strategic Combination to Create a Preeminent Cell Therapy Company for Solid Tumors (Newsfile)

Adaptimmune Therapeutics Plc is commercial-stage cell therapy company, which focuses on providing novel cell therapies to people with cancer. Its clinical pipeline includes Afami-cel, Lete-cel, and ADP-A2M4CD8. The company was founded by Bent K. Jakobsen, James Julian Noble, and Helena Katrina Tayton-Martin in 2008 and is headquartered in Abingdon, the United Kingdom.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Piccina Cintia	Chief Commercial Officer	Jun 18 '24	Sale	0.93	24,531	22,814	38,293	Jun 18 05:00 PM
Rawcliffe Adrian	Chief Executive Officer	Jan 17 '24	Sale	0.67	30,080	20,244	44,848	Jan 17 05:31 PM
Rawcliffe Adrian	Chief Executive Officer	Jan 16 '24	Sale	0.79	9,304	7,350	14,104	Jan 17 05:31 PM
Norry Elliot	Chief Medical Officer	Jan 17 '24	Sale	0.67	18,276	12,300	7,785	Jan 17 05:31 PM
Norry Elliot	Chief Medical Officer	Jan 16 '24	Sale	0.79	2,287	1,807	3,363	Jan 17 05:31 PM
Lunger John	Chief Patient Supply Officer	Jan 17 '24	Sale	0.67	18,114	12,191	7,785	Jan 17 05:30 PM
Lunger John	Chief Patient Supply Officer	Jan 16 '24	Sale	0.79	4,681	3,698	7,023	Jan 17 05:30 PM
Bertrand William C JR	Chief Operating Officer	Jan 17 '24	Sale	0.67	18,908	12,725	7,785	Jan 17 05:30 PM
Bertrand William C JR	Chief Operating Officer	Jan 16 '24	Sale	0.79	4,681	3,698	7,023	Jan 17 05:30 PM
Norry Elliot	Chief Medical Officer	Jan 12 '24	Sale	0.85	7,799	6,661	11,841	Jan 12 05:00 PM
Norry Elliot	Chief Medical Officer	Jan 11 '24	Sale	0.84	4,009	3,354	6,104	Jan 12 05:00 PM
Bertrand William C JR	Chief Operating Officer	Jan 12 '24	Sale	0.85	5,220	4,458	7,874	Jan 12 05:00 PM
Bertrand William C JR	Chief Operating Officer	Jan 11 '24	Sale	0.84	4,009	3,354	6,104	Jan 12 05:00 PM
Rawcliffe Adrian	Chief Executive Officer	Jan 12 '24	Sale	0.85	17,257	14,739	26,388	Jan 12 05:00 PM
Rawcliffe Adrian	Chief Executive Officer	Jan 11 '24	Sale	0.84	11,945	9,994	18,395	Jan 12 05:00 PM
Lunger John	Chief Patient Supply Officer	Jan 12 '24	Sale	0.85	5,220	4,458	7,874	Jan 12 05:00 PM
Lunger John	Chief Patient Supply Officer	Jan 11 '24	Sale	0.84	4,009	3,354	6,104	Jan 12 05:00 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

Adaptimmune Therapeutics Plc ADR

Upgrade your FINVIZ experience